With Synaptogenix’s clinical trial failure regarding its Alzheimer's drug candidate, SNPX stock tumbled on the broader implications. More
Articles
Two Stocks Following Megatrends Into 2023
Follow these macroeconomic trends into 2023 and beyond. More
Former Nikola CEO Mark Russell Keeps Selling NKLA Stock
Since Sept. 15, former Nikola CEO Mark Russell has sold 75,000 shares of NKLA stock nearly every day. What's going on? More
LCID Stock News: Lucid Opens Third European Retail Location
Today, investors in Lucid Group and LCID stock received some promising news, but that wasn't enough to take shares higher. More
History Says the Fed Will Pivot in February, Ending the Bear Market
The probabilities strongly favor a Fed pivot following this stock market tantrum. That will end the bear market – and bring a stock boom. More
PLTR Stock Alert: What to Know About Palantir’s Newest Partnership
Today, investors in Palantir and PLTR stock are in selling mode, despite what appears to be a positive catalyst for the company. More
